Subscribe to RSS
Please copy the URL and add it into your RSS Feed Reader.
https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00000126.xml
Intensivmedizin up2date 2015; 11(03): 245-255
DOI: 10.1055/s-0041-103126
DOI: 10.1055/s-0041-103126
Operative Intensivmedizin
Update: Immunsuppression bei Organtransplantationen
Further Information
Publication History
Publication Date:
28 July 2015 (online)
![](https://www.thieme-connect.de/media/intensiv-u2d/201503/lookinside/thumbnails/234_10-1055-s-0041-103126-1.jpg)
Während noch immer Konzepte für eine auf den einzelnen Patienten maßgeschneiderte Immunsuppression gesucht werden, gibt es mittlerweile gute Strategien zur Einsparung von CNIs, die mit einer Reduktion der CNI-assoziierten Nebenwirkungen einhergehen. Insbesondere durch eine Induktionstherapie bei der Nierentransplantation können frühe Abstoßungsperioden reduziert, CNIs verzögert appliziert und Steroide frühzeitig ausgeschlichen werden. Die steroidfreie Immunsuppression nach Nierentransplantationen hat allerdings in den nationalen Leitlinien aufgrund des unklaren Nutzen-Risikoprofiles bisher keinen Einzug gehalten.
-
Literatur
- 1 Houben P, Gotthardt DN, Radeleff B et al. Complication management after liver transplantation: Increasing patient safety by standardized approach and interdisciplinary cooperation. Chirurg 2015; PMID: 25604306
- 2 Starzl TE, Groth CG, Brettschneider L et al. Orthotopic homotransplantation of the human liver. Ann Surg 1968; 168: 392-415
- 3 Zand MS. Immunosuppression and immune monitoring after renal transplantation. Semin Dial 2005; 18: 511-519
- 4 Geissler EK, Schlitt HJ. Immunosuppression for liver transplantation. Gut 2009; 58: 452-463
- 5 Turner AP, Knechtle SJ. Induction immunosuppression in liver transplantation: a review. Transpl Int 2013; 26: 673-683
- 6 Mangus RS, Fridell JA, Vianna RM et al. Immunosuppression induction with rabbit anti-thymocyte globulin with or without rituximab in 1000 liver transplant patients with long-term follow-up. Liver Transpl 2012; 18: 786-795
- 7 Gotthardt DN, Bruns H, Weiss KH et al. Current strategies for immunosuppression following liver transplantation. Langenbeck’s Arch Surg 2014; 399: 981-988
- 8 Préville X, Flacher M, LeMauff B et al. Mechanisms involved in antithymocyte globulin immunosuppressive activity in a nonhuman primate model. Transplantation 2001; 71: 460
- 9 Xing T, Huang L, Yu Z et al. Comparison of steroid-free immunosuppression and standard immunosuppression for liver transplant patients with hepatocellular carcinoma. PLoS One 2013; 8: e71251
- 10 Verna EC, Farrand ED, Elnaggar AS et al. Basiliximab induction and delayed calcineurin inhibitor initiation in liver transplant recipients with renal insufficiency. Transplant 2011; 91: 1254-1260
- 11 Ramirez CB, Doria C, Frank AM et al. Completely steroid-free immunosuppression in liver transplantation: a randomized study. Clin Transplant 2013; 27: 463-471
- 12 De Simone P, Nevens F, De Carlis L et al. Everolimus with reduced tacrolimus improves renal function in de novo liver transplant recipients: a randomized controlled trial. Am J Transplant 2012; 12: 3008-3020
- 13 Saliba F, De Simone P, Nevens F et al. Renal function at two years in liver transplant patients receiving everolimus: results of a randomized, multicenter study. Am J Transplant 2013; 13: 1734-1745
- 14 Fischer L, Klempnauer J, Beckebaum S et al. A randomized, controlled study to assess the conversion from calcineurin-inhibitors to everolimus after liver transplantation (PROTECT). Am J Transplant 2012; 12: 1855-1865
- 15 Sterneck M, Kaiser GM, Heyne N et al. Everolimus and early calcineurin inhibitor withdrawal: 3-year results from a randomized trial in liver transplantation. Am J Transplant 2014; 14: 701-710
- 16 Rodriguez-Peralvarez M, Manousou P, Lerut J et al. How much immunosuppression is needed after liver transplantation?. Clin Transplant 2014; 28: 6-7
- 17 Kidney Disease:Improving Global Outcomes (KDIGO) Transplant Work Group. KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J of Transplant 2009; 9 (Suppl. 03) S1-S155
- 18 Préville X, Flacher M, LeMauff B et al. Mechanisms involved in antithymocyte globulin immunosuppressive activity in a nonhuman primate model. Transplantation 2001; 71: 460
- 19 Pearl JP, Parris J, Hale DA et al. Immunocompetent T-cells with a memory-like phenotype are the dominant cell type following antibody-mediated T-cell depletion. Am J Transplant 2005; 5: 465
- 20 Tydén G, Ekberg H, Tufveson G et al. A randomized, double-blind, placebo-controlled study of single dose rituximab as induction in renal transplantation: a 3-year follow-up. Transplantation 2012; 94: e21
- 21 Morath C, Süsal C. Transplantation: rituximab induction only for sensitized kidney recipients?. Nat Rev Nephrol 2013; 9: 703-705
- 22 Webster AC, Playford EG, Higgins G et al. Interleukin 2 receptor antagonists for renal transplant recipients: a meta-analysis of randomized trials. Transplantation 2004; 77: 166
- 23 Wiland AM, Fink JC, Weir MR et al. Should living-unrelated renal transplant recipients receive antibody induction? Results of a clinical experience trial. Transplantation 2004; 77: 422
- 24 Brennan DC, Daller JA, Lake KD et al. Rabbit antithymocyte globulin versus basiliximab in renal transplantation. N Engl J Med 2006; 355: 1967
- 25 Hardinger KL, Brennan DC, Schnitzler MA. Rabbit antithymocyte globulin is more beneficial in standard kidney than in extended donor recipients. Transplantation 2009; 87: 1372
- 26 Miller JT, Collins CD, Stuckey LJ et al. Clinical and economic outcomes of rabbit antithymocyte globulin induction in adults who received kidney transplants from living unrelated donors and received cyclosporine-based immunosuppression. Pharmacotherapy 2009; 29: 1166
- 27 Haider I, Cahill M. Fatal thrombocytopaenia temporally related to the administration of alemtuzumab (MabCampath) for refractory CLL despite early discontinuation of therapy. Hematology 2004; 9: 409
- 28 Webster AC, Woodroffe RC, Taylor RS et al. Tacrolimus versus ciclosporin as primary immunosuppression for kidney transplant recipients: meta-analysis and meta-regression of randomised trial data. BMJ 2005; 331 : 810
- 29 Atkison P, Joubert G, Barron A et al. Hypertrophic cardiomyopathy associated with tacrolimus in paediatric transplant patients. Lancet 1995; 345 : 894
- 30 Gaston RS. Maintenance immunosuppression in the renal transplant recipient: an overview. Am J Kidney Dis 2001; 38 (Suppl. 06) S25
- 31 Ekberg H, Tedesco-Silva H et al. ELITE-Symphony Study. Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med 2007; 357: 2562-2575
- 32 Vincenti F, Charpentier B, Vanrenterghem Y et al. A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study). Am J Transplant 2010; 10: 535
- 33 Masson P, Henderson L, Chapman JR et al. Belatacept for kidney transplant recipients. Cochrane Database of Systematic Reviews 2014;
- 34 Pascual J, Zamora J, Galeano C et al. Steroid avoidance or withdrawal for kidney transplant recipients. Cochrane Database of Systematic Reviews 2009;
- 35 Montero N, Webster AC, Royuela A et al. Steroid avoidance or withdrawal for pancreas and pancreas with kidney transplant recipients. Cochrane Database of Systematic Reviews 2014;
- 36 Webb NJ, Douglas SE, Rajai A et al. Corticosteroid-Free Kidney Transplantation Improves Growth: 2-Year Follow-up of the TWIST Randomized Controlled Trial. Transplantation 2014; 99: 1178-1185
- 37 Woodside KJ, Schirm ZW, Noon KA et al. Fever, infection, and rejection after kidney transplant failure. Transplantation 2014; 97: 648-653
- 38 Augustine JJ, Woodside KJ, Padiyar A et al. Independent of nephrectomy, weaning immunosuppression leads to late sensitization after kidney transplant failure. Transplantation 2012; 94: 738-743
- 39 Del Bello A, Congy-Jolivet N, Sallusto F et al. Donor-specific antibodies after ceasing immunosuppressive therapy, with or without an allograft nephrectomy. Clin J Am Soc Nephrol 2012; 7: 1310
- 40 Shapiro R, Carroll PB, Tzakis AG et al. Adrenal reserve in renal transplant recipients with cyclosporine, azathioprine, and prednisone immunosuppression. Transplantation 1990; 49: 1011
- 41 Ratcliffe PJ, Dudley CR, Higgins RM et al. Randomized controlled trial of steroid withdrawal in renal transplant recipients receiving triple immunosuppression. Lancet 1996; 348 : 643
- 42 Andrews PA. Standards Committee of the British Transplantation Society. Summary of the British Transplantation Society Guidelines for management of the failing kidney transplant. Transplantation 2014; 98: 1130
- 43 European Association for the Study of the Liver. EASL Recommendations on Treatment of Hepatitis C. 2015 Im Internet: http://www.easl. eu/research/our-contributions/clinical-practice-guidelines/detail/recommendations-on-treatment-of-hepatitis-c-2015/report/1